GlaxoSmithKline Competition Analysis

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC competes with Astrazeneca PLC, Bristol Myers, Johnson Johnson, and Eli Lilly; as well as few others. The company runs under Healthcare sector within Drug Manufacturers?General industry. Analyzing GlaxoSmithKline PLC competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio related equities across multiple sectors and You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of GlaxoSmithKline PLC competition on your existing holdings. Please check GlaxoSmithKline PLC Correlation with its peers.

Search Competition

 
Refresh
The current Return on Investment is estimated to increase to 23.20. The current Return on Average Assets is estimated to increase to 0.07GlaxoSmithKline PLC Return on Average Assets are decreasing as compared to previous years. The last year's value of Return on Average Assets was reported at 0.07. The current Tangible Assets Book Value per Share is estimated to increase to 14.38, while Goodwill and Intangible Assets are estimated to decrease to under 32.9 B.

Specify up to 10 symbols:

Comparable Analysis

    
 Better Than Average     
    
 Worse Than Peers or Benchmark    View Performance Chart
GSK
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>GP</div>
AZN
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>AP</div>
BMY
<div class='circular--portrait-small' style='font-weight: 700;background:#689CFD;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>BM</div>
JNJ
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>JJ</div>
LLY
<div class='circular--portrait-small' style='font-weight: 700;background:#006400;color: #FFE4E1;font-size:1.1em;padding-top: 10px;;'>EL</div>
MRK
<div class='circular--portrait-small' style='font-weight: 700;background:#008000;color: #f8f8f8;font-size:0.9em;padding-top: 12px;;'>MRK</div>
NVS
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>NO</div>
GILD
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>GS</div>
GRFS
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>GS</div>
GWPH
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;padding-top: 10px;;'>GP</div>
 0.88 
 41.22 
GlaxoSmithKline PLC
 0.90 
 53.80 
Astrazeneca PLC
 0.49 
 59.14 
Bristol Myers
 0.42 
 140.97 
Johnson Johnson
 0.32 
 163.87 
Eli Lilly
 0.84 
 78.78 
Merck
 0.32 
 87.57 
Novartis
 0.38 
 76.35 
Gilead Sciences
 2.41 
 18.70 
Grifols S
 0.67 
 125.35 
GW Pharmaceuticals
Market Volatility
(30 Days Market Risk)
Market Performance
(30 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(30 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Price to Earnings To Growth
Current Liabilities
Total Asset
Short Ratio
Last Dividend Paid
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Did You Try This Idea?

Run Transportation Thematic Idea Now

Transportation
Transportation Theme
Fama and French focuses on testing asset pricing under different economic assumptions. Transportation theme has 61 constituents.
View All  Next Launch Transportation
Please check GlaxoSmithKline PLC Correlation with its peers. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page